Treatment of neuropathic pain: Focus on antidepressants, opioids and gabapentin

C Peter N Watson MD FRCPC1, Judith H Watt-Watson RN PhD2

BACKGROUND: The treatment of neuropathic pain continues to be difficult. Randomized, controlled trials (RCTs) provide some evidence to guide therapy. Most data relate to antidepressant therapy, although there is information on anticonvulsants and other treatments. Mistaken beliefs about many of these treatments are prevalent and need to be dispelled. Opioids are increasingly being used for the refractory patient. There has been recent enthusiasm for the anticonvulsant gabapentin for the treatment of these conditions.

OBJECTIVE: To review the positive scientific data that are largely confined to RCTs in two neuropathic pain conditions that have proved to be good models for clinical investigation. These models are postherpetic neuralgia and painful diabetic neuropathy. Negative RCTs, weakly positive RCTs, other types of treatments and neuropathic conditions are also examined.

METHODS: This review of the literature used MEDLINE, CINAHL and the Cochrane Database.

RESULTS: There is extensive literature supporting the use of the older generation antidepressants, such as amitriptyline, in neuropathic pain. Newer RCTs support the use of gabapentin and opioids. Other therapies may be useful in individual cases on a trial and error basis but are largely unsupported by RCTs at this time.

CONCLUSIONS: First-line therapy for neuropathic pain may be either an older generation antidepressant, such as amitriptyline or nortriptyline, or the anticonvulsant gabapentin. A variety of trial and error approaches may be used, none of which has sound scientific approval. For refractory patients, chronic opioid therapy may be the only avenue of relief. There has been recent enthusiasm for the anticonvulsant gabapentin for the treatment of these conditions.

Key Words: Neuropathic pain; Pain treatment

Traitement de la douleur neurogène : Accent sur les antidépresseurs, les opiacés et la gabapentine

HISTORIQUE : Le traitement de la douleur neurogène reste complexe. Des essais randomisés contrôlés (ERC) donnent quelques indications pour orienter le traitement. La plupart des données concernent le traitement aux antidépresseurs, bien qu’il y ait aussi des données sur les traitements aux anticonvulsivants et autres. Certains préjugés à l’endroit de bon nombre de ces traitements sont fort répandus et méritent d’être combattus. Les opiacés sont de plus en plus utilisés dans ce contexte pour traiter les cas rebelles. Récemment, l’anticonvulsivant gabapentine a fait l’objet d’un intérêt soutenu pour le traitement de ce type d’affection.

OBJECTIF : Passer en revue les données scientifiques positives émanant d’essais randomisés contrôlés sur le traitement de deux types de douleur neurogène et qui se sont révélés être de bons modèles de recherche clinique. Ces modèles sont la névralgie post-zostérienne et la neuropathie diabétique. On a également étudié les ERC négatifs, les ERC faiblement positifs et autres types de traitements et de maladies neurogènes.

MÉTHODES : Cette revue de la littérature a été effectuée à partir d’une interrogation des réseaux MEDLINE et CINAHL et de la base de données Cochrane.

RÉSULTATS : La littérature abonde à l’appui de l’utilisation des antidépresseurs de génération antérieure, comme l’amitriptyline, pour soigner la douleur neurogène. Les essais cliniques randomisés contrôlés plus récents appuient l’utilisation de la gabapentine et des

1Department of Medicine and 2Faculty of Nursing, University of Toronto, Toronto, Ontario

Correspondence and reprints: Dr C Peter N Watson, 89 Humber College Boulevard, Suite 104, Toronto, Ontario M9V 1B8. Telephone 416-239-3494, fax 416-239-6365

Received for publication March 19, 1999. Accepted June 8, 1999.
For the easing of neuro-traumatic pain we tried, in turn, the whole range of medicines known as narcotics, such as hyoscyamus, daturia, atropia, and morphia. None of them, save the last, seemed, when singly used, to be of the slightest value, and one by one they were laid aside until in the vast mass of cases the salts of morphia alone were employed. Silas Weir Mitchell 1872 (1).

Although the above quotation was written over a century and a quarter ago, we are only now entering an era in which opioids are gaining acceptability for the treatment of painful neuropathies and other nonmalignant pain. The present article reviews the renaissance of this treatment approach, the use of the newest agent gabapentin and the extensive literature on what has been, for some years, the standard therapy – the older antidepressants. These approaches all have support from randomized, controlled trials (RCTs), mainly in treating two clinical conditions. The reader should be aware and perhaps cautioned that although this report is in part evidence based, it also reviews uncontrolled clinical data.

For the purposes of this review, neuropathic pain is defined as pain caused by injury or dysfunction in the peripheral or central nervous system (2). The term peripheral neuropathic pain is used for peripherally generated pain (nerve or nerve root), and the term central pain is applied to pain arising from the spinal cord or more rostral areas in the central nervous system. Trigeminal neuralgia (tic douloureux), although a neuropathic pain, is not discussed. It is a rather unique condition occurring only in the head, with specific and usually successful medical and surgical management to which a large amount of literature has been devoted. Also not discussed is complex regional pain syndrome (reflex sympathetic dystrophy) because it is a subject in itself. Tables 1 and 2 list some of the broad range of conditions that may be encompassed under the rubric of peripheral neuropathic and central pain, respectively.

Neuropathic pain is a common problem in patients seen by chronic pain specialists and is difficult to treat even in sophisticated hands. For many of these persistent, painful conditions there are no controlled trials, and so mistaken beliefs have arisen that need to be dispelled. Examples of incorrect beliefs are that carbamazepine is the drug of choice for lancing and other neuropathic pain outside the head, that phenothiazines are useful adjuncts to antidepressants or as sole therapy, and that opioids are ineffective and to be avoided because of the potential for physical and psychological dependency and tolerance. We attempt to dispel these mistaken beliefs and clarify what medication, in our view, is most effective, based largely on scientific data. This review focuses on two peripheral neuropathic pain conditions for which there is good scientific data, postherpetic neuralgia (PHN) and painful diabetic neuropathy (PDN) (Table 3) and on the RCTs relating to central pain. We also raise the issue of whether pre-emptive or early and aggressive treatment of acute pain may prevent progression to a chronic painful state.

MATERIALS AND METHODS
MEDLINE, CINAHL and the Cochrane Database were searched for RCTs on neuropathic pain generally and on PHN and PDN specifically. A recent critical review (3) ex-
TABLE 3
Ratings and effectiveness of clinical trials for postherpetic neuralgia and painful diabetic neuropathy

<table>
<thead>
<tr>
<th>Agent</th>
<th>Author, year (reference)</th>
<th>Rating/Result</th>
<th>Author, year (reference)</th>
<th>Rating/Result</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antidepressants</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>Watson et al, 1982 (11)</td>
<td>6/6 +</td>
<td>Turkington, 1980 (41)</td>
<td>+</td>
</tr>
<tr>
<td></td>
<td>Max et al, 1989 (12)</td>
<td>79/9 +</td>
<td>Max et al, 1987 (43)</td>
<td>76/9 +</td>
</tr>
<tr>
<td></td>
<td>Watson et al, 1992 (16)</td>
<td>69/ +</td>
<td>Max et al, 1992 (45)</td>
<td>79/ +</td>
</tr>
<tr>
<td></td>
<td>Watson et al, 1998 (17)</td>
<td>69/ +</td>
<td>Max et al, 1991 (44)</td>
<td>72/ +</td>
</tr>
<tr>
<td>Desipramine</td>
<td>Kirsh-Kumar et al, 1990</td>
<td>72/ +</td>
<td>Maprotiline</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(15)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anticonvulsants</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenytoin</td>
<td>Chadda and Mathur, 1978</td>
<td>63/ +</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>(57)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carbamazepine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Saul et al, 1977 (58)</td>
<td>71/ –</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Wilton, 1974 (55)</td>
<td>68/ +</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rull et al, 1969 (54)</td>
<td>54/ +</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Opioids</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morphine, intravenous</td>
<td>Rowbotham et al, 1991 (30)</td>
<td>68/ +</td>
<td>Kastrup et al, 1987 (85)</td>
<td>68/ +</td>
</tr>
<tr>
<td>Morphine, intravenous</td>
<td>Eide et al, 1994 (82)</td>
<td>71/ –</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Codeine, oral</td>
<td>Watson et al, 1998 (32)</td>
<td>70/ +</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Agents</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lidocaine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intravenous</td>
<td>Rowbotham et al, 1991 (30)</td>
<td>68/ +</td>
<td>Kastrup et al, 1987 (85)</td>
<td>68/ +</td>
</tr>
<tr>
<td>Topical</td>
<td>Rowbotham et al, 1995 (33)</td>
<td>75/ +</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Capsaicin, topical</td>
<td>Bernstein et al, 1989 (86)</td>
<td>67/ +</td>
<td>Capsaicin Study Group, 1991 (67)</td>
<td>76/ +</td>
</tr>
<tr>
<td>Mexiletine</td>
<td>Watson, 1994 (36)</td>
<td>82/ –</td>
<td>Chad et al, 1990 (88)</td>
<td>60/ –</td>
</tr>
<tr>
<td>Ketamine, intravenous</td>
<td>Eide et al, 1994 (82)</td>
<td>71/ +</td>
<td>Deigard et al, 1988 (78)</td>
<td>79/ +</td>
</tr>
<tr>
<td>Ketamine, subcutaneous</td>
<td>Eide et al, 1995 (81)</td>
<td>43/ +</td>
<td>Stracke et al, 1992 (79)</td>
<td>75/ –</td>
</tr>
<tr>
<td>Clonidine, topical</td>
<td></td>
<td></td>
<td>Zeigler et al, 1992 (75)</td>
<td>70/ –</td>
</tr>
<tr>
<td>Clonidine, oral</td>
<td>Max et al, 1998 (77)</td>
<td>78/ +</td>
<td>Byas-Smith et al, 1995 (76)</td>
<td>73/ +</td>
</tr>
<tr>
<td>Nonsteroidal anti-inflammatory drugs</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>By mouth</td>
<td>Max et al, 1998 (77)</td>
<td>78/ –</td>
<td>Cohen and Harris, 1987 (80)</td>
<td>52/ +</td>
</tr>
<tr>
<td>Topical</td>
<td>Benedetti et al, 1992 (89)</td>
<td>65/ –</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Benedetti and Lorenzetti, 1996 (90)</td>
<td>70/ –</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lorazepam</td>
<td>Max et al, 1998 (12)</td>
<td>79/ –</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Numerical rating are from reference 3. See Table 4 for how the ratings were determined. Trials appearing twice are crossover comparisons of two drugs.

+ Effective; – Not effective
amine some 50 RCTs in peripheral neuropathic pain. The purpose of the review is not to duplicate this thorough and excellent work, but rather to compare and contrast the clinical research on PHN and PDN as the primary models used in this area of clinical investigation. Publications relating to central pain and other neuropathic pain are also included. The RCTs rated by the method of Kingery (3) have their maximum potential score out of 100 listed under the rating columns in Table 3. Kingery scored the trials he received according to the criteria in Table 4. Where no ratings appear, the study was not rated by Kingery because it is not an RCT or is a more recent RCT. Uncontrolled or nonblinded data were included where no other information exists. None of the RCTs critically and favourably reviewed by Kingery fulfilled all the criteria for an ideal study as outlined in Table 4, or in the Consolidated Standards of Reporting Trials (CONSORT) statement (4). Valuable information may be found in preliminary, less rigorous investigations where no other data exist. However, all the trials discussed here were published in peer-reviewed journals, and most were rated highly in the critical review mentioned above.

### TABLE 4
**Scoring criteria for the evaluation of methods in controlled clinical trials for peripheral neuropathic pain from Kingery (3)**

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Criteria Weight</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Study population</strong></td>
<td></td>
</tr>
<tr>
<td>Inclusion/exclusion criteria listed</td>
<td>2</td>
</tr>
<tr>
<td>Randomized</td>
<td>6</td>
</tr>
<tr>
<td>Number of subjects in smallest group after 15 randomizations (three points for each 10 subjects up to 50 subjects)</td>
<td>15</td>
</tr>
<tr>
<td>No baseline difference between groups for Duration of symptoms</td>
<td>2</td>
</tr>
<tr>
<td>Outcome measures</td>
<td>8</td>
</tr>
<tr>
<td>Patient attrition at last outcome measure &lt;20%</td>
<td>2</td>
</tr>
<tr>
<td>&lt;10%</td>
<td>2</td>
</tr>
<tr>
<td><strong>Interventions</strong></td>
<td></td>
</tr>
<tr>
<td>Treatment protocol explicitly described</td>
<td>3</td>
</tr>
<tr>
<td>Comparison with placebo treatment</td>
<td>8</td>
</tr>
<tr>
<td>Comparison with another treatment dose or placebo with side effects</td>
<td>5</td>
</tr>
<tr>
<td><strong>Effect</strong></td>
<td></td>
</tr>
<tr>
<td>Blinded patients</td>
<td></td>
</tr>
<tr>
<td>Attempted blinding</td>
<td>4</td>
</tr>
<tr>
<td>Blinding evaluated and successful</td>
<td>4</td>
</tr>
<tr>
<td>Blinded outcome assessment</td>
<td>4</td>
</tr>
<tr>
<td>Outcome measures: two points for each measure, maximum score of 10</td>
<td>10</td>
</tr>
<tr>
<td>Longest follow-up period comparing outcome measures among groups (one point for each week after onset of treatment up to 13 weeks)</td>
<td>13</td>
</tr>
<tr>
<td><strong>Data presentation and analysis</strong></td>
<td></td>
</tr>
<tr>
<td>Statistical tests for effect differences between treatment groups (P&lt;0.05)</td>
<td>12</td>
</tr>
<tr>
<td>Maximum possible score</td>
<td>100</td>
</tr>
</tbody>
</table>

PHN is a common cause of chronic pain in the elderly population. The eruption of herpes zoster (HZ), the most common neurological illness (5), is a harbinger of persistent neuropathic pain for at least 50% of those over 60 years of age (6). Although the natural progression is one of slow improvement in some patients, many patients suffer for years. Our experience is that a judicious choice of medication and careful monitoring result in satisfactory control for approximately 70% of patients. About 30% of patients remain inadequately relieved or have intractable pain. The prevention of HZ by vaccination of the elderly, along with early aggressive treatment of acute zoster pain, may be crucial for this group (7).

As in other neuropathies, steady burning, or aching and paroxysmal lancinating pain may occur. These symptoms may occur spontaneously and are often aggravated by tactile contact with the involved skin such as friction from even the lightest clothing. Paradoxically, firm pressure may provide some relief.

Examination of the affected, scarred skin often reveals both a loss of sensation to pinprick, temperature and touch over a wider area than the scars, and an area of sensitive or painful skin. This sensitive area of skin may be much larger than that occupied by the scarring or anesthetic area but paradoxically may include the anesthetic areas and be elicited by a different type of stimulation (skin stroking or skin traction between thumb and forefinger). An explanation may be that these latter stimuli may cause a summation effect on hypersensitive, deafferented, central neurons with expanded receptive fields.

PHN is a particularly good model of neuropathic pain for drug trials. Patients with PHN who have pain that is fairly stable over time can be found in sufficient numbers for these studies.
Antidepressant therapy, as opposed to many other putative therapies for this difficult problem, has an established scientific basis. Woodforde et al (8) were the first to recognize that amitriptyline could afford relief in truly chronic postherpetic pain patients. They thought that all 14 of the subjects in their open-label trial were depressed and this was the rationale for using amitriptyline. They initially used a dose of 10 mg four times per day and this was gradually increased to 25 mg four times per day, which achieved good pain relief in 11 patients that lasted one to 11 months.

Taub (9) reported treating successfully five sufferers of PHN of greater than three months’ duration using amitriptyline combined with a phenothiazine (fluphenazine, perphenazine or thioridazine). In a later publication, Taub and Collins (10) used a daily dose of 75 mg of amitriptyline along with fluphenazine 1 mg three times per day in 17 patients with postherpetic pain of greater than one year’s duration. Patients reported good relief in both studies, with some mild residual pain at three to six years of follow-up. Taub and Collins (10) believed that amitriptyline alone was ineffective and that it was best used to combat the depressant action of the other drugs. Subsequently, this regimen came into widespread use.

Clinical experience has convinced us that amitriptyline prescribed alone results in pain relief in PHN and that phenothiazines alone are ineffective. Most patients are not depressed except mildly in some cases as a secondary response to pain. A double-blind, placebo controlled, crossover trial of amitriptyline was conducted in 24 patients with this disorder (11). All patients had PHN of more than three months’ duration, and good results were achieved in 16 of 24 (67%). Because most patients were not depressed and reported pain relief without a change in depression ratings, the drug appeared to result in pain relief that was independent of an antidepressant effect. This analgesia occurred at lower doses (median 75 mg) than those usually used to treat depression. Follow-up was for a median of 12 months, with good results maintained in 12 of 22 patients (55%). The use of small doses (10 to 25 mg) to start followed by small increments resulted in few significant side effects. A subsequent trial has corroborated these results (12). Amitriptyline has limitations for long term use because of side effects, and because relief is rarely complete and occurs in only about two-thirds of patients.

One action of this drug is that it potentiates both serotonin and noradrenaline in the central nervous system. These neurotransmitters are thought to be involved in pain-inhibiting systems descending from the brainstem to the dorsal horn of the spinal cord. Subsequent research has explored whether selective serotoninergic or noradrenergic agents might be more effective and have fewer side effects. Our experience with serotoninergic agents (clomipramine, trazodone, nefasdone, fluoxetine and zimelidine) in PHN has been disappointing (13,14). The evidence supporting the use of noradrenergic agents is more compelling. Desipramine, a selective noradrenaline reuptake inhibitor, has proved to be more effective than placebo in this disease, and pain relief with this drug also has not been mediated by improvement in depression (15). Although desipramine is reported to have fewer side effects, it is not known how it compares with amitriptyline. A randomized, double-blind trial, comparing maprotiline (noradrenergic) with amitriptyline, attempted to answer the question as to whether such an agent possessed greater analgesia and effectiveness for PHN (16). Although amitriptyline was found to be more effective, nine patients responded equally well to both drugs and seven responded only to maprotiline. Thus, 16 of 32 patients (50%) completing the trial may have had predominantly noradrenergic pain-inhibiting systems, whereas eight other responders required an agent with an effect on both serotonin and noradrenaline (amitriptyline). Patients reported that all three aspects of the pain of PHN responded to treatment, that is, steady pain, jabbing pain and pain on tactile skin contact. Side effects were troublesome with both agents, thus limiting their effectiveness. Again, most patients were not depressed, and pain relief occurred without a change in depression-rating scales. A recent trial has demonstrated that nortriptyline (noradrenergic) is equal to amitriptyline in relieving PHN and has fewer side effects (17). It was, therefore, concluded that the initial antidepressant of choice in PHN is amitriptyline or nortriptyline. If these fail, we recommend a selective noradrenergic agent such as desipramine or maprotiline.

There are no well designed, placebo controlled trials of a phenothiazine in the treatment of PHN. For the most part, the beneficial effects seen with the combination of an antidepressant and phenothiazine appear to be due to the antidepressant, the efficacy of which has been proved by controlled trials. Occasionally, patients have improved on different phenothiazines, but it is not clear whether the improvement was due to the drug, a placebo effect or a sedative effect, or was a result of the natural history of pain resolution.

Studies using the anticonvulsants carbamazepine, phenytoin and valproic acid for PHN have been either unimpressive or difficult to interpret because of the concomitant use of antidepressants (18-20). Although carbamazepine is a popular agent for treating paroxysmal lancinating pain, there is no conclusive evidence to justify its use in PHN, and clinical experience points to limited efficacy. Gabapentin has proved to be superior to placebo in PHN, with 43% of patients reporting good or moderately good improvement (versus 12% with placebo) (21). Because of the apparent occurrence of fewer significant side effects with gabapentin than with antidepressant therapy, it has been suggested as a first-line treatment for this condition (21).

For a long time there has been a bias against using opioids for nonmalignant pain. There is now increasing support for the view that they are helpful and justifiable for selected patients (22-28). There are also uncontrolled observations suggesting that opioids relieve neuropathic pain. Uncontrolled data related to a long acting oral opioid (29) and single dose intravenous controlled trials (30-31) have supported the effectiveness of opioids in PHN. Our experiences with PHN have indicated that opioids are useful for some patients with this condition (14). Twenty-five of 90 patients with otherwise...
intractable pain achieved good to excellent results, and 50 others had 25% to 50% relief (14). A controlled trial of oxy
codone in PHN has shown that 58% of patients experience at
least moderately improved pain versus 18% with placebo
(32). We continue to follow many postherpetic patients who
are otherwise refractory to all the usual approaches. Often
these patients receive renewed prescriptions for opioids, and
patients rarely develop problems with tolerance or depend-
ency. Usually, complete pain relief does not occur, which is
similar to the effect of antidepressant therapy. Although
opioids may reduce the severity of the pain, improvement is
often modest; however, the improvement is often enough
that patients choose to continue using these drugs. There
appears to be a ceiling effect with opioids in PHN; below the
celing some relief occurs, and above the ceiling no further
pain relief occurs but side effects supervene to a point where
doze escalation is refused.

A variety of short acting opioids are available for the
treatment of PHN, including morphine, hydromorphone, an-
ileridine, levorphanol, codeine and oxycodone. Sustained-
release preparations also seem to be advantageous and in-
clude morphine, oxycodone, hydromorphone, and the fentanyl patch. Shorter acting agents may be used with these for
rescue doses. Patients may respond better to one particular
opioid than another, making a trial and error approach justi-

Intravenous lidocaine has been shown to relieve PHN
(30). More practically, a lidocaine patch has proved to be su-
perior to placebo in this condition (33,34). Uncontrolled data
suggest that topical acetylsalicylic acid in various vehicles
may help this pain (35). Topical capsaicin has been difficult
to study because blinding is impossible due to the burning in-
duced by capsaicin (36). Our clinical experiences indicate
that the effect of these agents are modest at best and that for
most patients they are not useful as sole therapy.

For the truly intractable 30% of patients, the prevention of
PHN by vaccination of the elderly and early aggressive treat-
ment of acute zoster (37,38) may limit inflammation and cen-
tral neuronal hyperactivity. This prophylactic approach is
almost entirely hypothetical, except for antiviral trials that
indicate a modest effect at reducing PHN.

**PAINFUL DIABETIC NEUROPATHY**

PDN is common and comprises a number of diagnostic cate-
gories. Pharmacological approaches are based on a few clini-
cal trials and clinical experience. It is not possible to tailor
therapy to pain mechanisms. The role of diet, insulin and
good diabetic control is important in the prevention and reso-

As with PHN, considerable information about PDN
comes from RCTs of antidepressants. Most of the evidence
suggests that, of this group, the older antidepressants are
most effective for relieving this type of neuropathic pain.
Some early studies of antidepressants in PDN have been dif-
cult to interpret because of the concomitant use of phe-

Max et al (45) found amitriptyline to be superior to diazepam in a double-blind trial
and thought relief accompanied amelioration of masked depression. Kvinesdal et al (42) found that imipramine was superior to placebo and commented that none of their patients
were depressed, that pain relief was seen earlier and that
blood levels were lower than those seen with an antidepress-

Max et al (43) found amitriptyline to be superior to ac-
tive placebo in PDN. They observed that the drug produced
relief of both the steady and the lancinating pain, that higher
doses were associated with greater relief, and that relief oc-
curred in depressed and nondepressed patients. Max et al (44)
reported that desipramine (noradrenergic) was more effec-
tive than active placebo with this pain. Relief was greater in
depressed patients, but improvement was also noted in non-
depressed individuals. Another study by Max et al (45) found
that desipramine provided relief similar to that provided by
amitriptyline, both being superior to placebo, but that fluo-
xetine (serotonergic) showed no advantage. A trial of mapro-
tiline (a noradrenergic antidepressant) found that it was
effective in both diabetic and nondiabetic neuropathies (46),
but less so than amitriptyline.

Single-blind (47) and double-blind (48) trials of imipra-
mine (serotonergic and noradrenergic) have demonstrated its
superiority to placebo. Imipramine was also found to be su-
perior to mianserin (5-hydroxytriptamine antagonist, nora-

Max et al (44) found amitriptyline to be superior to ac-
tive placebo in PHN. They observed that the drug produced
relief of both the steady and the lancinating pain, that higher
doses were associated with greater relief, and that relief oc-
curred in depressed and nondepressed patients. Max et al (44)
reported that desipramine (noradrenergic) was more effec-
tive than active placebo with this pain. Relief was greater in
depressed patients, but improvement was also noted in non-
depressed individuals. Another study by Max et al (45) found
that desipramine provided relief similar to that provided by
amitriptyline, both being superior to placebo, but that fluo-
xetine (serotonergic) showed no advantage. A trial of mapro-
tiline (a noradrenergic antidepressant) found that it was
effective in both diabetic and nondiabetic neuropathies (46),
but less so than amitriptyline.

Other trials, both single-blind (50) and double-blind (51),
have shown an effect from the serotonergic antidepressant,
paroxetine. RCTs have found the serotonergic antidepressant
clopi-mazine, to be superior to desipramine (noradrenergic)
(52) and the serotonergic drug citalopram (53) to be superior
to placebo in this type of neuropathic pain. These latter trials
differ from research in PHN in that they indicate an effect
from serotonergic agents in PDN that has not been shown in
PHN.

The anticonvulsant carbamazepine has been reported to
be effective in two double-blind, placebo controlled trials
(54,55). A large placebo effect was present in both studies,
and it is difficult to know how effective the drug was in pro-
ducing satisfactory relief. A carbamazepine open-label trial
of 54 patients indicated complete relief in 44 (56). Two con-
trolled trials of phenytoin have produced conflicting results
(57,58). An open-label trial of phenytoin found that 68% of 60
patients had excellent results (59). Uncontrolled observa-
tions suggested to one author that clonazepam was useful for
some patients (60). Gabapentin has recently been shown to be
superior to placebo in an RCT, with 60% of patients hav-
ing at least moderate improvement (versus 33% with pla-
cebo) (61). Because it has fewer side effects than antidepress-
ants, it has been suggested as a first-line therapy.

Mexiletine is an oral local anesthetic-like drug, that has
been effective in one small RCT of PDN at higher doses (62)
but not effective in the range of 225 to 675 mg daily seen in
another study (63).
There are no controlled trials of opioids for treating this condition. Tramadol is a centrally acting analgesic with an effect on opioid receptors and also on the reuptake of noradrenaline and serotonin. This agent was found to be effective in PDN by RCT (64).

A number of studies have examined the use of topical capsaicin in PDN (36). These have been very difficult to appraise because of a large placebo effect and the impossibility of blinding due to the burning induced by capsaicin.

OTHER PERIPHERAL NEUROPATHIC PAIN

Well controlled trials do not exist for the variety of other peripheral neuropathic pains listed in Table 1 (excluding trigeminal neuralgia). Topical capsaicin may be useful for some patients with the incisional neuralgia called postmastectomy pain syndrome (36), but the trials have been impossible to blind satisfactorily. Although Mitchell (1) recognized that opioids relieved causalgia at the time of the American Civil War, their abuse and overdose led to the opioid phobia that has been such a hindrance for so long.

CENTRAL PAIN

Some of the various central painful states are listed in Table 2. There is little scientific or good anecdotal information therapeutically about most of these individual conditions.

A three-phase, placebo controlled trial of amitriptyline and carbamazepine in patients with central poststroke pain demonstrated a statistically significant reduction in pain with amitriptyline (65). Another RCT found no effect of trazodone (a serotonin potentiating antidepressant) in spinal cord injury pain (66). Desipramine trials have shown that this noradrenaline-potentiating antidepressant may relieve central pain (67). These results are of interest because they parallel the research discussed already in the peripheral neuropathic pain disorders of PHN and PDN. Carbamazepine appears to be effective for trigeminal neuralgia, painful tonic seizures and other central pain due to multiple sclerosis, based on clinical experience and uncontrolled published observations. No controlled trials exist for anticonvulsants or opioids in central pain. A widespread belief exists that this type of pain is opioid-resistant. This perception may, however, be generated in part by the fear of these agents and, hence, a hesitancy to use them to their full potential.

DISCUSSION

Much of the clinical research with antidepressants in PHN and PDN has produced similar results. That is, the older, less selective antidepressants seem to be most effective. Noradrenergic agents, although useful, may have a weaker analgesic action. The more selective serotonergic agents appear to be ineffective or much less effective for most patients with PHN but may be of greater value in PDN. Reasons for this apparent difference in the effect of serotonergic drugs between the two disorders may be differences in pain mechanisms or the lack of similar studies in PHN. The serotonergic studies in PDN are also small in number, and it is difficult to determine the clinical effectiveness of the drugs because a statistical difference in efficacy may not translate into good relief and patient satisfaction. The trials of antidepressants in central pain, although few, tend to support those in peripheral neuropathic pain. These findings are in keeping with those of a recent systematic review of antidepressants in neuropathic pain (68). The anticonvulsant gabapentin may be useful for neuropathic pain and appears to have fewer side effects than antidepressants. Carbamazepine may be useful for some cases of PDN, for trigeminal neuralgia (the drug of choice) and for pain syndromes in multiple sclerosis (69).

Practical therapeutic guidelines

From the preceding discussion it is clear that for many specific types of neuropathic pain there is limited scientific information to guide the clinician. The following recommendations are, in part, based on clinical experience as well as what is known from the RCTs in PHN and PDN. These findings provide a reasonable basis for general guidelines that may be applied to any such pain, until more specific data are available on individual pain mechanisms and new therapies.

Antidepressant Therapy: Although an argument has been put forth for gabapentin (21,61), it is not known how it compares with the standard therapy, the older antidepressants. It is our belief that the first-line therapy for most neuropathic pain should be amitriptyline or nortriptyline. The latter may be preferable because it has fewer side effects (17). The median dose that relieves this pain in some trials is 50 to 75 mg; however, the dose may vary widely. Because of this variability and because side effects are problematic with the older antidepressants, it is suggested that treatment start with a low dose. In patients less than 65 years of age a starting dose of 25 mg is suggested, and with those older than 65 years of age, 10 mg. It is prudent to prescribe pre-emptively a stool softener such as docusate sodium and a mouth spray to deal with constipation and dry mouth, respectively. Patients should be cautioned about the possibility of other important side effects such as drowsiness, weight gain and, in the older male, urinary retention. These drugs may be given in a single bedtime dose. Every seven to 10 days the dose can be increased by 10 to 25 mg until satisfactory pain relief occurs or unacceptable side effects supervene. Blood levels are only of use as a guide to compliance and to substantiate the clinical impression (eg, lack of a dry mouth) that a further increase is possible. The presence of a dry mouth may be a good indication that the drug is reaching a significant level in the blood. There is no therapeutic range of blood levels for pain relief. The final dose may be as little as 5 mg or more than 200 mg. If amitriptyline and nortriptyline fail, it is worth trying a more noradrenergic agent such as desipramine or maprotiline using a similar dosing escalation schedule. Antidepressant therapy commonly reduces the pain from moderate or severe to mild in one-half to two-thirds of patients, with complete relief being unusual. Side effects often have to be accepted if they are tolerable or manageable. In diabetic neuropathy, there is evidence that imipramine as well as the serotonergic agents clomipramine and paroxetine may be effective.
Anticonvulsants: Anticonvulsants may be useful if antidepressants fail. Gabapentin may become a first-line agent for neuropathic pain. It is so recommended by some authors (21,61) because there appear to be fewer side effects than with other therapies and efficacy is thought to be comparable. Doses of up to 3600 mg/day have been suggested. Carbamazepine may be considered first-line treatment for trigeminal neuralgia and for the various pain syndromes of multiple sclerosis such as painful tonic seizures. This drug may be started at a dose of 100 mg two to three times per day. The dose may be increased after a week or two to 200 mg two to three times per day and thereafter to a level that produces pain relief or drowsiness or other side effects as an end point. Drug levels in the blood may be a guide to compliance and dose escalation. Sustained-release preparations can be particularly useful to improve tolerability and compliance. Phenytoin may be initiated at a dose of 100 mg daily at bedtime for the elderly patient or 300 mg daily at bedtime for a younger patient with blood levels used as a guide to dose increases and compliance, and titration to pain relief or side effects. Other potentially useful anticonvulsants are clonazepam and valproic acid, using the guidelines available in any pharmacological reference source. Whether the combination of an antidepressant with an anticonvulsant such as gabapentin is useful is not clear, but this may be considered for difficult cases where pain is incompletely relieved by one agent.

Opioids: The use of opioids for neuropathic pain when all else has failed remains contentious but has growing support from both clinical trials and survey data. Clinical experience indicates that when these drugs are used for pain, the risk of psychological dependence (addiction) is low, and problems with physical dependence and tolerance do not occur in most patients. It is important to know this because opioids may be the only avenue of relief for many patients with severe neuropathic pain. Complete relief is unusual, and the aim is to make pain more tolerable and to improve quality of life. It is advisable to follow certain guidelines if opioids are used. This is good medical practice but also protects the clinician in the face of scrutiny by regulatory bodies. The following guidelines are suggested:

- Use a single prescriber
- Use a single pharmacy
- Schedule regular visits (every one to three months) and document the drug, the strength and number of pills prescribed and the clinical status (pain levels with and without the drug used, quality of life and side effects)
- Attach a copy of the prescription to the chart (either carbon impression or photocopy), at the patient visit note site
- Create a flow sheet showing drug, strength and number of pills prescribed at each visit
- Avoid prescribing for patients with a history of chemical dependency (there are exceptions to this rule)

Cease therapy if drug-seeking behaviour occurs

- Solicit written testimonials from significant others to as to the treatment benefits, be incorporated in the chart.

Other guidelines are also available (70-74).

It is worth trying another opioid if the first one fails because one may be more effective than another for an individual patient or type of neuropathic pain. Short acting opioids include codeine, morphine, oxycodone, hydromorphone and anileridine. The dose may be slowly increased every few days depending on response, side effects and drug pharmacokinetics. It is reasonable to prescribe an antinauseant and a stool softener, particularly in a patient using opioids for the first time. Once a response is achieved with a short acting opioid a switch can be made to a longer acting opioid such as sustained-release morphine, which may be more convenient, have fewer side effects and be more effective for chronic pain. Short acting opioids may still be necessary for acute episodes. Other sustained-release preparations are available such as sustained-release oxydodone, hydromorphone and a skin patch for fentanyl. Methadone usage requires special knowledge as well as a special license and in our view should be at least initiated by those sophisticated in its use. Our patients often report that although they obtain increasing relief with increasing doses of an opioid, a ceiling is reached beyond which only more side effects are encountered so that escalation beyond that point does not occur. Opioids may be combined with antidepressant or anticonvulsant therapy. It may be useful to begin with a low dose of antidepressant at bedtime and provide intermittent doses of a short acting opioid. At subsequent visits, the dose of antidepressant can be increased as suggested above, and at the same time the clinician can evaluate the effectiveness of the opioid. It is important to use very small initial doses of any of these agents with the elderly. Also, with a patient of any age, the maxim of ‘start low and go slow’ is a good one, and for patients who appear to be sensitive to drugs, monotherapy at therapy initiation is prudent.

Topical agents: The topical agents that have been studied most frequently for neuropathic pain are capsaicin and nonsteroidal anti-inflammatory drugs (NSAIDs), particularly acetylsalicylic acid and local anesthetics. The use of topical agents under an commercially available occlusive dressing or plastic food wrap, may provide greater efficacy but can often also cause skin irritation. A topical lidocaine skin patch may be particularly valuable (34).

Capsaicin is the active ingredient in red peppers and other pepper plants and is thought to act by depleting substance P and other peptides in small primary afferents (36). It needs to be applied repeatedly (three to four times daily) over three weeks. A strong burning sensation induced by this compound during initial treatment may be intolerable. Capsaicin has been impossible to study in controlled trials because of the burning sensation. Acetylsalicylic acid is usually crushed (eg, two tablets) and mixed in a vehicle (30 mls of either or chloroform or Vaseline intensive care lotion (Unilever, New
York) and applied to the painful hyperesthetic skin as needed. Topical ether and chloroform must, of course, be used carefully, particularly in elderly patients. Local anesthetics such as lidocaine (33-35) or a eutectic mixture of local anesthetics (AstraZeneca, Mississauga, Ontario) may also be applied as needed. In our experience, topical approaches are rarely useful as sole therapy except in the occasional patient but may be a useful adjunct to other therapeutic agents.

Miscellaneous treatments
For patients who are desperate there are a variety of trial and error approaches, none of which is scientifically secure. Although they do not help most patients, they are worth trying because occasionally individuals appear to respond. Also discussed here are treatments that have been studied and appear to be of little use such as the N-methyl-D-aspartate (NMDA) inhibitors now available.

Serotonin reuptake inhibitors: The newest family of antidepressants, serotonin uptake inhibitors, do not appear to have good pain relieving properties. Some patients, however, say they feel better or cope better with the pain while taking these drugs. Some of the choices in this drug class are fluoxetine, fluvoxamine, sertraline and paroxetine. In our clinical experience, doses of fluoxetine in the range of 40 to 60 mg may be more effective than 20 mg, if tolerated.

Clonidine: Clonidine has been studied in PDN (75,76) and in PHN (77) but does not appear to be of practical use.

Mexiletine and lidocaine: The orally active local anesthetic agents mexiletine and lidocaine seem to improve chronic neuropathic pain in some patients (78,79). Doses range from 225 to 750 mg in controlled trials, and higher doses may be more effective. Blood level measurements for this drug do not seem to be of practical value, and caution should be exercised in administering mexiletine with antidepressants.

Baclofen: Baclofen can be used alone for trigeminal neuralgia or in conjunction with carbamazepine. However, its use for other neuropathies has not been demonstrated by RCTs. Our clinical experience indicates that it does not provide good results for most patients. Reasonable doses range from 10 to 20 mg three times per day.

Acetaminophen and NSAIDs: Acetaminophen and NSAIDs usually are not useful for neuropathic pain (77,80), but occasionally patients may find them beneficial. Acetaminophen should be used with caution because of the potential for hepatotoxicity with chronic use. If used, regular liver function tests are recommended, and doses should be limited to less than 2000 to 4000 mg/day. If acetaminophen with codeine or oxycodone is used it is prudent to try to switch to the opioid alone. Responses to NSAIDs in chronic pain may be idiosyncratic; therefore, trials of different categories of agents may be warranted. Enteric-coated preparations of acetylsalicylic acid and naproxen, or diclofenac combined with misoprostol (Arthrotec, Searle Canada, Mississauga, Ontario) are of possible use in reducing gastrointestinal upset. Cyclo-oxygenase-II (COX-2) inhibitors are now available. These do not have the side effects of other available NSAIDs and may prove to be useful.

NMDA antagonists: The available NMDA antagonists are ketamine and dextromethorphan. Parenteral ketamine has been effective in PHN (81,82). High doses of dextromethorphan in an RCT have demonstrated an effect in PDN (83). However, because of side effects and limited efficacy, NMDA antagonists cannot be regarded as practical, at this time, for these conditions.

Transcutaneous electrical nerve stimulation, acupuncture and relaxation therapy: There are many nonpharmacological approaches for the treatment of neuropathic pain. In our view, anything that is safe and reasonably economical is worth a try in truly desperate patients. However, referral of these patients for behaviour modification therapy, without initiation or continuation of pharmacological approaches, in the presence of a clear history and with signs of neuropathic pain, is naive and callous.

Nerve blocks: Regional anesthesia (nerve block therapy) has a long history and is widely used for neuropathic pain, particularly complex regional pain syndrome. Although there is scant good science to support using this therapy for peripheral neuropathic pain, a trial in competent hands is reasonable in refractory patients. Relief with this approach does not predict relief by surgical deafferentation.

Surgery: The only neuropathic pain problem responding well to surgery is trigeminal neuralgia. Surgical deafferentation for other nerve injury is usually not useful and may aggravate the condition. Stimulation procedures (dorsal column and deep brain stimulation) may be of use in selected intractable patients, but initial surgical success is about 50% at best.

Prevention of neuropathic pain
There is evidence that acute severe pain (eg, the severing of a nerve during surgery under general anesthesia or acute HZ) may create a state of central neuronal hyperexcitability that may provide the substrate for persistent pain. It is possible that this may be prevented during surgery by pre-emptive local anesthetic blockade and perioperative opioids (84). Pre-emptive treatment is, however, not possible for nonsurgical acute pain such as HZ, but for this condition, early aggressive relief of the acute pain may prevent the transition to PHN (38). Examples of this type of aggressive relief include nerve blocks, antiviral agents, early antidepressant therapy and prompt treatment with adequate analgesics and opioids if required. The efficacy of most of these methods has not yet been proven, but they appear to be reasonable and safe. The advent of the varicella vaccination is another approach that, when available for the elderly patient, may prevent HZ and, hence, postherpetic pain. Better diabetic control may contribute to a reduction in long term complications such as painful neuropathies. Protection of the nerves during operations such as thoracotomy and careful dissection may minimize nerve trauma and reduce the incidence and severity of post-thoracotomy pain and other incisional neuralgias.

CONCLUSIONS
Steady but slow progress has been made in clarifying the effective treatment of neuropathic pain. It is possible to provide satisfactory relief for more than half of the sufferers of these
conditions. Spontaneous improvement may also occur over time even with long standing pain. Better therapies are needed. Research in PHN, PDN and central pain, with regard to antidepresant therapy, is similar, that is, some of the older antidepressants appear to be most effective. Possible differences are that some serotonergic antidepressants and some anticconvulsants may be more effective in PDN and that the NMDA antagonist dextromethorphan appears to have a weak effect in PDN but not PHN. Pre-emptive approaches and early aggressive treatment of acute pain may be useful in preventing progression to a chronic painful state.

REFERENCES
47. Sindrup SH, Gram LF, Skjold T, Froland A, Beck-Nielsen H.
Watson and Watson


Submit your manuscripts at http://www.hindawi.com